Background and aim: Secondary loss of response to adalimumab (ADA-LOR) commonly occurs in patients with Crohn's disease (CD) treated with adalimumab (ADA).
Acute heart failure (AHF) is a leading cause of admission in emergency departments (ED).
Results from a new study presented in an oral presentation at the Annual European Congress of Rheumatology (EULAR 2018) show...
Objective: To assess the prevalence of obstructive sleep apnoea (OSA) in men presenting with erectile dysfunction (ED) at a single centre.
The FDA has approved Cialis (tadalafil) tablets, the PDE 5 inhibitor marketed for erectile dysfunction ,from Eli Lilly Company, for...
Vivus, Inc. announced that the European Commission (EC) has adopted the implementing decision granting marketing authorization for Spedra (avanafil) for...
Emerging neuromodulation devices show promise for expanding acute treatment options. Over the past few years, there has been a growth in research investigating the efficacy and safety of non-invasive neuromodulation, which delivers electrical or magnetic stimulation to nerves or neural tissue, for the management of acute attacks of migraine
Background: Asthma exacerbations are frequent in patients with severe disease. This report describes results from two retrospective cohort studies describing exacerbation frequency and risk, emergency department (ED)/hospital re-admissions, and asthma-related costs by asthma severity in the US and UK.
The FDA has approved Stendra (avanafil) tablets, from Vivus Inc, for the treatment of Erectile Dysfunction (ED). The approval is...
The CHMP in the EU has recommended approval of Cialis (tadalafil), from Eli Lilly and Co, for once daily use...